• Though the technology is only a research tool now, it might be just what’s needed to bring some promising new cancer and HIV therapies to patients.
  • SQZ says it may be able to significantly cut the costs of immunotherapy and improve its effectiveness, factors that have prevented it from being commercialized
  • SQZ’s devices are currently being used by a number of biologists, and the company is in the early stages of testing it for use with experimental treatments.

Share This Article